Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Urinary alkalization increases urine elimination of all the following drugs, except:

Amphetamine. ### Explanation The core principle behind this question is **Ion Trapping**, which is based on the **Henderson-Hasselbalch equation**. This concept dictates that a drug in its ionized (charged) form cannot easily cross lipid membranes and is therefore trapped in the renal tubules, leading to increased excretion. **1. Why Amphetamine is the Correct Answer:** Amphetamine is a **weak base**. According to the principle of ion trapping, weak bases are ionized in **acidic environments**. Therefore, to increase the renal elimination of Amphetamine, the urine must be **acidified** (e.g., using Ammonium Chloride). Alkalizing the urine would make Amphetamine non-ionized, promoting its reabsorption back into the bloodstream. **2. Why the Other Options are Incorrect:** * **Salicylate (A):** Aspirin is a weak acid. Alkalizing the urine (using Sodium Bicarbonate) converts it into its ionized form, preventing reabsorption and promoting excretion. This is a standard treatment for salicylate poisoning. * **Methotrexate (B):** This is a weak acid. Urinary alkalization is clinically used during high-dose methotrexate therapy to increase its solubility and excretion, preventing crystal-induced nephrotoxicity. * **Phenobarbital (C):** A long-acting barbiturate and a weak acid. Alkalization of urine is a mainstay in managing its toxicity to enhance renal clearance. **High-Yield Clinical Pearls for NEET-PG:** * **Rule of Thumb:** "Like dissolves in like, but opposites ionize." * **Acidic drugs** (Salicylates, Barbiturates, MTX) $\rightarrow$ Excreted in **Alkaline urine**. * **Basic drugs** (Amphetamines, Morphine, Quinine) $\rightarrow$ Excreted in **Acidic urine**. * **Agent for Alkalization:** IV Sodium Bicarbonate ($NaHCO_3$). * **Agent for Acidification:** Ammonium Chloride ($NH_4Cl$) or Vitamin C (though rarely used clinically due to risk of metabolic acidosis).

Q: Chloroquine is given in a high loading dose primarily because of which pharmacokinetic property?

High volume of distribution. **Explanation:** **1. Why High Volume of Distribution (Vd) is correct:** Chloroquine is a highly lipophilic drug that exhibits extensive tissue binding, particularly in the liver, spleen, kidneys, and melanin-containing tissues (like the retina). This results in an exceptionally high **Volume of Distribution (Vd)**—often exceeding 10,000 L. In pharmacokinetics, the **Loading Dose (LD)** is calculated using the formula: $LD = Vd \times Target\ Plasma\ Concentration$. Since Chloroquine sequesters heavily into tissues, a large initial dose is required to saturate these tissue binding sites and rapidly achieve the therapeutic plasma concentration necessary to exert its antimalarial effect. Without a loading dose, it would take several weeks to reach a steady state. **2. Why other options are incorrect:** * **B. Poor gastrointestinal absorption:** Chloroquine is actually absorbed very rapidly and almost completely (>80%) from the GI tract. Poor absorption would necessitate parenteral administration, not a specific loading dose strategy. * **C. High first-pass metabolism:** Chloroquine does not undergo significant first-pass metabolism; its bioavailability is high. Drugs with high first-pass metabolism (like Nitroglycerin) are usually given via non-oral routes. **3. NEET-PG High-Yield Pearls:** * **Amiodarone and Digoxin** are other classic examples of drugs requiring loading doses due to high Vd and extensive tissue sequestration. * **Chloroquine Toxicity:** Due to its affinity for melanin, long-term use can lead to **"Bull’s eye maculopathy"** (retinopathy). * **Half-life:** Because of its high Vd, Chloroquine has a very long terminal half-life (30–60 days).

Q: Which of the following drugs has high plasma protein binding to serum albumin?

Warfarin. ### Explanation **1. Why Warfarin is Correct:** The binding of drugs to plasma proteins is primarily determined by their chemical nature. **Acidic drugs** [2] (like Warfarin [1], NSAIDs, Sulfonamides, and Phenytoin) bind predominantly to **Serum Albumin**. Warfarin is highly protein-bound (>99%) [1]. This is clinically significant because only the "free" fraction of the drug is pharmacologically active [3]. Drugs with high albumin binding are prone to displacement interactions; for example, if another drug displaces Warfarin from albumin, it can lead to a sudden increase in free Warfarin levels, resulting in hemorrhage. **2. Why Other Options are Incorrect:** * **Lignocaine & Quinidine:** These are **basic drugs**. Basic drugs do not primarily bind to albumin; instead, they bind to **$\alpha_1$-acid glycoprotein (AAG)** [4]. * **All of the above:** This is incorrect because the question specifically asks for binding to *serum albumin*, which is selective for acidic drugs. **3. High-Yield NEET-PG Pearls:** * **Albumin vs. AAG:** Remember the mnemonic: **"A for A"** (Acidic drugs bind to Albumin) and **"B for B"** (Basic drugs bind to $\alpha_1$-acid glycoprotein/Beta-globulin). * **Clinical Impact:** High protein binding usually results in a **low Volume of Distribution ($V_d$)** because the drug is sequestered within the vascular compartment. * **Disease States:** In **Hypoalbuminemia** (e.g., Nephrotic syndrome, Cirrhosis), the dose of highly protein-bound drugs like Warfarin or Phenytoin must be reduced to avoid toxicity [2]. * **AAG Levels:** $\alpha_1$-acid glycoprotein is an acute-phase reactant; its levels increase during inflammation, surgery, or trauma, potentially decreasing the free fraction of basic drugs like Lignocaine [4].

Q: What is characteristic of an agonist?

Affinity with intrinsic activity of 1. ### Explanation In pharmacology, the interaction between a drug and its receptor is defined by two key parameters: **Affinity** (the ability of a drug to bind to a receptor) and **Intrinsic Activity/Efficacy** (the ability of a drug to activate the receptor and produce a biological response). **Why Option A is Correct:** An **Agonist** is a drug that possesses both affinity and maximal intrinsic activity. By convention, the intrinsic activity (IA) of a full agonist is **1**. This means that upon binding, the drug induces a conformational change in the receptor that triggers the maximum possible biological effect. **Analysis of Incorrect Options:** * **Option B (IA = 0):** This describes an **Antagonist**. An antagonist has affinity (it binds to the receptor) but zero intrinsic activity. It produces no response of its own but prevents an agonist from binding. * **Option C (IA = -1):** This describes an **Inverse Agonist**. These drugs bind to receptors that have "constitutive activity" (spontaneous activity in the absence of a ligand) and suppress this baseline activity, producing an effect opposite to that of an agonist. * **Partial Agonists (Note):** These have affinity but an intrinsic activity between **0 and 1**. **NEET-PG High-Yield Pearls:** 1. **Intrinsic Activity Scale:** * Full Agonist: 1 * Partial Agonist: >0 to <1 * Antagonist: 0 * Inverse Agonist: -1 2. **Clinical Correlation:** A partial agonist (e.g., **Pindolol** or **Buprenorphine**) can act as an antagonist in the presence of a full agonist by displacing it from receptors, a phenomenon known as "dual action." 3. **Potency vs. Efficacy:** Efficacy (Intrinsic Activity) is clinically more important than potency. A drug with higher efficacy is more effective for severe conditions, regardless of the dose required.

Q: A patient reaches a steady state level of lithium that produces toxic side effects. If he decides to discontinue his medication, how long would it take for his lithium blood levels to reach 25% of his original steady state levels, assuming a half-life of 22 hours for lithium?

44 hours. ### Explanation **1. Understanding the Correct Answer (D: 44 hours)** The elimination of drugs following **first-order kinetics** (like Lithium) occurs at a constant fractional rate. The time required for the plasma concentration of a drug to reduce by 50% is defined as its **half-life ($t_{1/2}$)**. To reach 25% of the steady-state concentration, the drug must undergo **two half-lives**: * **After 1st half-life:** Concentration drops to 50% of the original level. * **After 2nd half-life:** Concentration drops to 25% (half of 50%). Given the $t_{1/2}$ of Lithium is 22 hours: $2 \times 22 \text{ hours} = \mathbf{44 \text{ hours}}$. **2. Analysis of Incorrect Options** * **Option A (11 hours):** This represents half of a half-life ($0.5 \times t_{1/2}$), which does not correspond to a standard elimination milestone. * **Option B (22 hours):** This is exactly one half-life. At this point, the concentration would be 50%, not 25%. * **Option C (33 hours):** This represents 1.5 half-lives. At this stage, the concentration would be approximately 35.3%. **3. Clinical Pearls for NEET-PG** * **Steady State Rule:** It takes approximately **4 to 5 half-lives** to reach steady-state concentration ($C_{ss}$) and the same amount of time to completely eliminate a drug from the body (>95% washout). * **Lithium Kinetics:** Lithium is handled by the kidneys similarly to sodium. Dehydration, NSAIDs, and Thiazide diuretics can decrease its clearance, leading to toxicity. * **Therapeutic Index:** Lithium has a **narrow therapeutic index** (0.6–1.2 mEq/L). Toxicity typically manifests at levels >1.5 mEq/L with symptoms like coarse tremors, ataxia, and seizures. * **First-Order vs. Zero-Order:** Most drugs follow first-order kinetics (constant percentage per unit time). Only a few follow zero-order (constant amount per unit time), such as **P**henytoin, **A**lcohol, and **W**arfarin/High-dose **A**spirin (Mnemonic: **PAW**).

Q: A drug has 80% absorption and a hepatic extraction ratio of 0.4. Calculate the bioavailability of the drug?

48%. ### Explanation **1. Understanding the Correct Answer (C: 48%)** Bioavailability ($F$) is the fraction of an administered dose that reaches the systemic circulation in an unchanged form. When a drug is given orally, it must first be absorbed from the gut and then pass through the liver (first-pass metabolism). The formula for systemic bioavailability is: **$F = f \times (1 - ER)$** * **$f$ (Absorption):** 80% or 0.8 * **$ER$ (Extraction Ratio):** 0.4 * **$(1 - ER)$ (Hepatic Escape Fraction):** This represents the fraction of the drug that escapes hepatic metabolism. Here, $1 - 0.4 = 0.6$ (or 60%). **Calculation:** $F = 0.8 \times 0.6 = 0.48$ $0.48 \times 100 = \mathbf{48\%}$ **2. Why Other Options are Incorrect** * **A (12%):** This is a mathematical error, likely from multiplying half of the extraction ratio by a fraction of the absorption. * **B (32%):** This occurs if you incorrectly multiply the absorption (0.8) by the extraction ratio (0.4) instead of the escape fraction. This represents the amount metabolized, not the amount reaching circulation. * **D (64%):** This value is obtained if one ignores the extraction ratio and applies a different coefficient, or incorrectly calculates $0.8 \times 0.8$. **3. NEET-PG High-Yield Clinical Pearls** * **Definition:** Bioavailability of an **Intravenous (IV)** dose is always **100% (F=1)**. * **First-Pass Effect:** Drugs with a high Hepatic Extraction Ratio (e.g., **Lidocaine, Propranolol, Nitroglycerin**) have low oral bioavailability and are often given via non-enteral routes. * **Area Under the Curve (AUC):** Bioavailability is calculated by comparing the AUC of oral administration to the AUC of IV administration: $F = \frac{AUC_{oral}}{AUC_{IV}}$. * **Clinical Significance:** If a drug’s ER is >0.7, its bioavailability will be low, and small changes in hepatic enzyme activity can lead to significant changes in plasma drug levels.

Q: Which of the following acts on nuclear receptors?

Thyroxine. **Explanation:** The correct answer is **Thyroxine (D)**. Receptors are classified based on their location and mechanism of action. **Nuclear receptors** are intracellular receptors that act as ligand-activated transcription factors. To reach these receptors, a drug must be lipid-soluble to cross the cell membrane. * **Thyroxine (T4/T3):** Although thyroid hormones are amino acid derivatives, they enter the cell via specific transporters and bind to receptors located directly on the **nucleus**. Once bound, they alter gene transcription, leading to the synthesis of new proteins. Other examples of drugs acting on intracellular/nuclear receptors include Steroids (Glucocorticoids, Mineralocorticoids, Sex hormones), Vitamin A, and Vitamin D. **Why other options are incorrect:** * **GABA (A):** Acts on **Ionotropic receptors** (GABA-A is a ligand-gated chloride channel) or Metabotropic receptors (GABA-B is G-protein coupled). * **Insulin (B):** Acts on **Enzyme-linked receptors** (specifically, Receptor Tyrosine Kinase) located on the cell membrane. * **Alpha-1 receptor (C):** This is a **G-Protein Coupled Receptor (GPCR)**, specifically the Gq subtype, which works via the IP3-DAG second messenger pathway. **High-Yield NEET-PG Pearls:** 1. **Fastest acting receptors:** Ion channels (milliseconds), e.g., Nicotinic ACh receptors. 2. **Slowest acting receptors:** Nuclear receptors (hours to days), as they require gene transcription and protein synthesis. 3. **Mnemonic for Cytoplasmic vs. Nuclear:** Most steroids bind in the **C**ytoplasm (except Estrogen/Thyroid), while **T**hyroid, **E**strogen, **V**itamin A & D bind directly in the **N**ucleus (**TEN**).

Question 1

Urinary alkalization increases urine elimination of all the following drugs, except:

Accepted Answer

Amphetamine

Answer

Salicylate

Answer

Methotrexate

Answer

Phenobarbital

Question 2

Chloroquine is given in a high loading dose primarily because of which pharmacokinetic property?

Accepted Answer

High volume of distribution

Answer

Poor gastrointestinal absorption

Answer

High first-pass metabolism

Answer

All of the above

Question 3

Which of the following statements regarding zero-order kinetics is true?

Accepted Answer

Clearance decreases with an increase in plasma concentration.

Answer

Half-life is constant.

Answer

The rate of elimination is dependent on plasma drug concentration.

Answer

It applies to the majority of drugs.

Question 4

Which of the following drugs has high plasma protein binding to serum albumin?

Accepted Answer

Warfarin

Answer

Lignocaine

Answer

Quinidine

Answer

All of the above

Question 5

What is characteristic of an agonist?

Accepted Answer

Affinity with intrinsic activity of 1

Answer

Affinity with intrinsic activity of 0

Answer

Affinity with intrinsic activity of -1

Answer

None of the above

Question 6

What is the typical outcome for a drug after undergoing Phase II biotransformation reactions?

Accepted Answer

Increased water solubility

Answer

Less bioreactive

Answer

Increased bioavailability

Answer

Increased lipid solubility

Question 7

A patient reaches a steady state level of lithium that produces toxic side effects. If he decides to discontinue his medication, how long would it take for his lithium blood levels to reach 25% of his original steady state levels, assuming a half-life of 22 hours for lithium?

Accepted Answer

44 hours

Answer

11 hours

Answer

22 hours

Answer

33 hours

Question 8

What is true about plasma half-life?

Accepted Answer

Half-life remains constant for drugs eliminated by first-order kinetics

Answer

Is the same as bioavailability

Answer

It is directly proportional to clearance

Answer

It is inversely proportional to volume of distribution

Question 9

A drug has 80% absorption and a hepatic extraction ratio of 0.4. Calculate the bioavailability of the drug?

Accepted Answer

48%

Answer

12%

Answer

32%

Answer

64%

Question 10

Which of the following acts on nuclear receptors?

Accepted Answer

Thyroxine

Answer

GABA

Answer

Insulin

Answer

Alpha-1 receptor

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?